242 related articles for article (PubMed ID: 36948568)
1. Effect of Intravenous Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation (EFFECT-KTx): rationale and study protocol for a double-blind, randomised, placebo-controlled trial.
Vinke JS; Eisenga MF; Sanders JF; Berger SP; Spikman JM; Abdulahad WH; Bakker SJ; Gaillard CAJM; van Zuilen AD; van der Meer P; de Borst MH
BMJ Open; 2023 Mar; 13(3):e065423. PubMed ID: 36948568
[TBL] [Abstract][Full Text] [Related]
2. Intravenous ferric derisomaltose in iron-deficient patients undergoing transcatheter aortic valve implantation due to severe aortic stenosis: study protocol of the randomised controlled IIISAS trial.
Bardan S; Kvaslerud AB; Andresen K; Kløve SF; Edvardsen T; Gullestad L; Broch K
BMJ Open; 2022 Sep; 12(9):e059546. PubMed ID: 36691165
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of the IRON-AF study: a double-blind, randomised, placebo-controlled study to assess the effect of intravenous ferric carboxymaltose in patients with atrial fibrillation and iron deficiency.
Tu SJ; Elliott AD; Hanna-Rivero N; Gallagher C; Mishima RS; Lyrtzis E; Wlochowicz D; Clarke NA; Roberts-Thomson KC; Stokes MB; Emami M; Lau DH; Sanders P; Wong CX
BMJ Open; 2021 Aug; 11(8):e047642. PubMed ID: 34373301
[TBL] [Abstract][Full Text] [Related]
4. A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status.
Bhandari S; Allgar V; Lamplugh A; Macdougall I; Kalra PA
BMC Nephrol; 2021 Mar; 22(1):115. PubMed ID: 33784968
[TBL] [Abstract][Full Text] [Related]
5. The effect of intravenous iron supplementation on exercise capacity in iron-deficient but not anaemic patients with chronic kidney disease: study design and baseline data for a multicentre prospective double-blind randomised controlled trial.
Greenwood SA; Beckley-Hoelscher N; Asgari E; Ayis S; Baker LA; Banerjee D; Bhandari S; Bramham K; Chilcot J; Burton J; Kalra PA; Lightfoot CJ; McCafferty K; Mercer TH; Okonko DO; Oliveira B; Reid C; Smith AC; Swift PA; Mangelis A; Watson E; Wheeler DC; Wilkinson TJ; Reid F; Macdougall IC
BMC Nephrol; 2022 Jul; 23(1):268. PubMed ID: 35896969
[TBL] [Abstract][Full Text] [Related]
6. Protocol and Baseline Data of a Multicentre Prospective Double-Blinded Randomized Study of Intravenous Iron on Functional Status in Patients with Chronic Kidney Disease.
Bhandari S; Allgar V; Lamplugh A; Macdougall IC; Kalra PA
Am J Nephrol; 2020; 51(6):493-500. PubMed ID: 32348985
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
Ponikowski P; Kirwan BA; Anker SD; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Haboubi T; Keren A; Khintibidze I; Kragten H; Martinez FA; McDonagh T; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Jankowska EA
Eur J Heart Fail; 2019 Dec; 21(12):1651-1658. PubMed ID: 31883356
[TBL] [Abstract][Full Text] [Related]
8. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.
McEvoy NL; Clarke JL; Mc Elvaney OJ; Mc Elvaney OF; Boland F; Hyland D; Geoghegan P; Donnelly K; Friel O; Cullen A; Collins AM; Fraughen D; Martin-Loeches I; Hennessy M; Laffey JG; Mc Elvaney NG; Curley GF
Trials; 2021 Apr; 22(1):288. PubMed ID: 33874981
[TBL] [Abstract][Full Text] [Related]
9. Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial.
Santer P; McGahey A; Frise MC; Petousi N; Talbot NP; Baskerville R; Bafadhel M; Nickol AH; Robbins PA
BMJ Open Respir Res; 2020 Jun; 7(1):. PubMed ID: 32565444
[TBL] [Abstract][Full Text] [Related]
10. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
[TBL] [Abstract][Full Text] [Related]
11. Intravenous iron supplement for iron deficiency in cardiac transplant recipients (IronIC): A randomized clinical trial.
Brautaset Englund KV; Østby CM; Rolid K; Gude E; Andreassen AK; Gullestad L; Broch K
J Heart Lung Transplant; 2021 May; 40(5):359-367. PubMed ID: 33612360
[TBL] [Abstract][Full Text] [Related]
12. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design.
Mentz RJ; Ambrosy AP; Ezekowitz JA; Lewis GD; Butler J; Wong YW; De Pasquale CG; Troughton RW; O'Meara E; Rockhold FW; Garg J; Samsky MD; Leloudis D; Dugan M; Mundy LM; Hernandez AF;
Circ Heart Fail; 2021 May; 14(5):e008100. PubMed ID: 34003690
[TBL] [Abstract][Full Text] [Related]
13. Intravenous Iron Replacement Improves Exercise Tolerance in COPD: A Single-Blind Randomized Trial.
Martín-Ontiyuelo C; Rodó-Pin A; Echeverría-Esnal D; Admetlló M; Duran-Jordà X; Alvarado M; Gea J; Barreiro E; Rodríguez-Chiaradía DA
Arch Bronconeumol; 2022 Oct; 58(10):689-698. PubMed ID: 35312562
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
16. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA; Keating GM
Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
[TBL] [Abstract][Full Text] [Related]
17. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.
Lewis GD; Malhotra R; Hernandez AF; McNulty SE; Smith A; Felker GM; Tang WHW; LaRue SJ; Redfield MM; Semigran MJ; Givertz MM; Van Buren P; Whellan D; Anstrom KJ; Shah MR; Desvigne-Nickens P; Butler J; Braunwald E;
JAMA; 2017 May; 317(19):1958-1966. PubMed ID: 28510680
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency.
Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh TA; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD
ESC Heart Fail; 2014 Sep; 1(1):52-58. PubMed ID: 28834668
[TBL] [Abstract][Full Text] [Related]
19. Ferric carboxymaltose and SARS-CoV-2 vaccination-induced immunogenicity in kidney transplant recipients with iron deficiency: The COVAC-EFFECT randomized controlled trial.
Vinke JSJ; Altulea DHA; Eisenga MF; Jagersma RL; Niekolaas TM; van Baarle D; Heiden MV; Steenhuis M; Rispens T; Abdulahad WH; Sanders JF; De Borst MH
Front Immunol; 2022; 13():1017178. PubMed ID: 36618359
[TBL] [Abstract][Full Text] [Related]
20. Effect of intravenous ferric carboxymaltose on exercise capacity and quality of life in patients with COPD : A pilot study.
Grasmuk-Siegl E; Urban MH; Scherrer S; Funk GC
Wien Klin Wochenschr; 2023 Jan; 135(1-2):35-44. PubMed ID: 36044093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
